Canada's NeuPath Q2 revenue up 25%, beats estimates

NeuPath Health

14/08/2025 12:43

Overview

NeuPath Q2 revenue rises 25% yr/yr, beating analyst expectations, per LSEG data

Adjusted EBITDA for Q2 up 69% yr/yr, reflecting operational improvements

Co cites strong demand for Arthrosamid

Outlook

NeuPath expects continued growth in the second half of 2025

Company plans further investments to enhance clinic network

NeuPath focuses on strategic opportunities for growth

Result Drivers

CAPACITY UTILIZATION - Improved capacity utilization to 84% in Q2 2025, up from 77% in Q2 2024, driven by stronger revenues and optimization of clinic space

ARTHROSAMID DEMAND - Strong early demand for Arthrosamid procedure contributed to revenue growth in Q2 2025

ONE-TIME PAYMENT - Revenue increase partly due to a one-time retroactive payment related to prior period physician reimbursements

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
C$23.60 mln
C$19.40 mln (1 Analyst)
Q2 Adjusted EBITDA
C$2.20 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for NeuPath Health Inc is C$0.50, about 49% above its August 13 closing price of C$0.26

Press Release: ID:nBw1HwYmTa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)